Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Standardizing Scavenger Receptor Nomenclature

Mercy PrabhuDas, Dawn Bowdish, Kurt Drickamer, Maria Febbraio, Joachim Herz, Lester Kobzik, Monty Krieger, John Loike, Terry K. Means, Soren K. Moestrup, Steven Post, Tatsuya Sawamura, Samuel Silverstein, Xiang-Yang Wang and Joseph El Khoury
J Immunol March 1, 2014, 192 (5) 1997-2006; DOI: https://doi.org/10.4049/jimmunol.1490003
Mercy PrabhuDas
*Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dawn Bowdish
†Department of Pathology and Molecular Medicine, McMaster Immunology Research Centre, M. G. DeGroote Institute of Infectious Disease Research, McMaster University, Hamilton, Ontario L8S 4K1, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kurt Drickamer
‡Department of Life Sciences, Imperial College, London SW7 2AZ, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Febbraio
§Department of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Katz Group Centre for Pharmacy and Health Research, Edmonton, Alberta T6G 2E1, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joachim Herz
¶Departments of Molecular Genetics, Neuroscience, and Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX 75390;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lester Kobzik
‖Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monty Krieger
#Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Loike
**Department of Physiology and Cellular Biophysics, Columbia University, New York, NY 10032;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terry K. Means
††Center for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soren K. Moestrup
‡‡Department of Biomedicine, University of Aarhus, 8000 Aarhus C, Denmark;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Post
§§Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72211;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatsuya Sawamura
¶¶Department of Vascular Physiology, Research Institute, National Cerebral and Cardiovascular Center, Suita, Osaka 565-8565, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Silverstein
‖‖Department of Physiology and Cellular Biophysics, Columbia University, New York, NY 10032;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiang-Yang Wang
##Department of Human and Molecular Genetics, Institute of Molecular Medicine, Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, VA 23298; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph El Khoury
***Infectious Disease Division, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Scavenger receptors constitute a large family of proteins that are structurally diverse and participate in a wide range of biological functions. These receptors are expressed predominantly by myeloid cells and recognize a variety of ligands, including endogenous and modified host-derived molecules and microbial pathogens. There are currently eight classes of scavenger receptors, many of which have multiple names, leading to inconsistencies and confusion in the literature. To address this problem, a workshop was organized by the U.S. National Institute of Allergy and Infectious Diseases, National Institutes of Health to help develop a clear definition of scavenger receptors and a standardized nomenclature based on that definition. Fifteen experts in the scavenger receptor field attended the workshop and, after extensive discussion, reached a consensus regarding the definition of scavenger receptors and a proposed scavenger receptor nomenclature. Scavenger receptors were defined as cell surface receptors that typically bind multiple ligands and promote the removal of non-self or altered-self targets. They often function by mechanisms that include endocytosis, phagocytosis, adhesion, and signaling that ultimately lead to the elimination of degraded or harmful substances. Based on this definition, nomenclature and classification of these receptors into 10 classes were proposed. The discussion and nomenclature recommendations described in this report only refer to mammalian scavenger receptors. The purpose of this article is to describe the proposed mammalian nomenclature and classification developed at the workshop and to solicit additional feedback from the broader research community.

Introduction

Scavenger receptor activity was first described by Drs. Michael Brown and Joseph Goldstein when they identified receptors in macrophages that endocytosed and degraded modified (acetylated), but not native, low-density lipoprotein (LDL) (1). Drs. Brown and Goldstein showed that these acetylated LDL receptors (LDLRs) recognized a wide variety of polyanionic ligands (2). Purification and cloning of the corresponding receptor protein and cDNA (3, 4) was soon followed by the identification of other modified LDLRs with broad binding specificity. In an initial attempt to systematically categorize these receptors, Dr. Monty Krieger proposed to subdivide them into “classes” (A, B, and so forth) based on their sequences, and each class was subdivided further into “types” based on additional variations in their sequences due to alternative splicing (5).

There are currently eight classes of scavenger receptors (classes A–H). In some cases multiple names have been assigned to the same receptor (e.g., MSR1, SR-AI, CD204, SCARA1). Additionally, there are proteins exhibiting scavenger receptor activity that have been named based on other criteria and have not been included in a general scavenger receptor nomenclature. Some examples include receptor for advanced glycation end products (RAGE), LRP1, LRP2, ASGP, CD163, scavenger receptor that binds phosphatidylserine and oxidized lipids (SR-PSOX), and CXCL16. New scavenger receptors also continue to be discovered and identified (6, 7). Therefore, it is important to convey consistent understanding and minimize redundancy and miscommunication in the scavenger receptor field. Developing a standardized nomenclature has the benefit of decreasing redundancy and facilitating communication and collaboration among investigators within a field, as well as in different fields, by building on a common understanding. Efforts to standardize other scientific nomenclatures have occurred in areas such as chemokines and their receptors (8), the TNF family of receptors involved in bone metabolism (9), complement peptide receptors (10), and glutamate receptors (11). Committees formed specifically for these processes by scientific societies or investigators in the field have developed systematic nomenclatures within each field for adoption by the broader scientific community.

To address the lack of a unified nomenclature system for scavenger receptors and better organize the field, the U.S. National Institute of Allergy and Infectious Diseases, National Institutes of Health, represented by Dr. Mercy PrabhuDas, initiated discussions with Dr. Joseph El Khoury and Prof. Siamon Gordon, which led to organizing and convening a workshop in which 15 investigators from five countries proposed a consensus definition of scavenger receptors and a systematic, standard nomenclature. We regret that Prof. Gordon was unable to participate in the workshop due to prior commitments. The workshop participants and their areas of expertise are listed in Table I.

View this table:
  • View inline
  • View popup
Table I. Workshop participants and their areas of expertise

The objectives of this workshop were to: 1) establish guidelines and recommendations for standardizing the nomenclature for scavenger receptors; 2) consider strategies for dealing with future discoveries of scavenger receptors; and 3) communicate the recommendations to the wider scientific community as a point of reference and for further discussion and final scavenger receptor nomenclature standardization. The discussion and nomenclature recommendations described in this report only refer to mammalian scavenger receptors.

Scavenger receptor background and history

The original description of scavenger receptors was in the context of studies of lipoproteins, atherosclerosis, and familial hypercholesterolemia (1, 12). Drs. Michael Brown and Joseph Goldstein had previously identified LDLRs and LDLR-mediated endocytosis and established that familial hypercholesterolemia was caused by loss of function mutations in the LDLR, which led to increased plasma LDL, premature atherosclerosis, and heart disease. Analysis of familial hypercholesterolemia patients showed that plasma LDL could also be partially cleared by an LDLR-independent pathway called the “scavenger pathway.” The earliest use of the term “scavenger receptor” to refer to the broad specificity receptor identified by Drs. Brown and Goldstein was in 1981 by Dr. Alan Fogelman and colleagues (13).

The first scavenger receptors were purified in 1988 (14) and cloned in 1990 (15, 16) by Dr. Monty Krieger’s group. These receptors initially were named type I and type II macrophage scavenger receptors and were found to be alternatively spliced products of a single gene. When additional scavenger receptors were identified, the type I and II macrophage receptors were renamed scavenger receptor, class A, type I and type II (SR-AI and SR-AII) by Dr. Krieger’s group. One distinct feature of the broad binding specificity of scavenger receptors was that they could recognize a large repertoire of ligands, ranging from bacteria and yeast to self (native proteins) and modified-self targets (2, 17–21). Besides playing a role in host defense, class A scavenger receptors were shown to be involved in functions such as homeostasis, Ag presentation, and pathogenesis of neurodegenerative disorders (22, 23).

Based on their broad ligand-binding specificities and expression in macrophages, Dr. Krieger and colleagues proposed that scavenger receptors could serve as pattern recognition receptors for innate immunity (5). Work done by groups led by Drs. Siamon Gordon, Tatsuhiko Kodama, and Joseph El Khoury provided direct evidence that the class A receptors are adhesion receptors, and that they recognize Gram-positive bacteria and β-amyloid, confirming the broad ligand specificity for these receptors (24, 25). Additional members of the class A scavenger receptors such as macrophage receptor with collagenous structure (MARCO) (26) and SCARA5 (27) were subsequently identified and shown to be involved in host defense.

Since the first discovery of the class A scavenger receptors, other multiligand pattern recognition receptors were independently identified, including CD14 (28), mannose receptors (29), and CD36 (30). There are currently eight classes of scavenger receptors, and summaries of each class of scavenger receptors are included under the proposed nomenclature recommendations below.

Scavenger receptor nomenclature recommendations

Prior to initiating a discussion about nomenclature, the workshop participants developed a definition of scavenger receptors, incorporating the various facets and characteristics of these receptors. This definition was used as the benchmark against which proposed nomenclatures were considered. As mentioned above, scavenger receptors were originally defined as cell surface proteins that bound chemically modified lipoproteins with high affinity. Additional characteristics included the ability to bind multiple ligands (broad-binding specificity), mediate endocytosis, in some cases mediate signaling, and act as innate immune pattern recognition receptors. Based on the discussion, the group agreed on the following working definition: Scavenger receptors are cell surface receptors that typically bind multiple ligands and promote the removal of non-self or altered self targets. They often function by mechanisms that include endocytosis, phagocytosis, adhesion, and signaling that ultimately lead to the elimination of degraded or harmful substances.

Fig. 1 illustrates the consensus nomenclature formula agreed on at the meeting. As an example, a scavenger receptor belonging to class A would be designated as SR-A1, where SR stands for scavenger receptor and is followed by a hyphen, then a capital letter representing the class of SR, and then an Arabic numeral representing the type of molecule within the class. Alternate splice variants are designated by a dot and an Arabic numeral following the type of molecule within the class (e.g., SR-A1.1). The numbering is based on the order in which the molecules were identified. Tables II and III provide the current and proposed nomenclature for human and mouse scavenger receptors. The following sections provide a brief overview of the currently known scavenger receptor classes and the proposed nomenclature for each class and member, as recommended by the workshop participants.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Proposed scavenger receptor nomenclature formula. Proposed nomenclature formula: SR stands for scavenger receptor. SR is followed by a hyphen, then a capital letter representing the class of SR (A–J) followed by an Arabic numeral representing the type of molecule within the class (the numbering is based on the order in which the molecules were identified). Alternatively spliced forms of a molecule will be designated as 1.1, 1.2, and so forth. For existing spliced variants, the longest variant in terms of amino acid sequence will be given the first number.

View this table:
  • View inline
  • View popup
Table II. Summary of current mouse scavenger receptor nomenclature and proposed changes
View this table:
  • View inline
  • View popup
Table III. Summary of current human scavenger receptor nomenclature and proposed changes

Class A scavenger receptors: SR-A.

Class A scavenger receptors are expressed primarily on tissue macrophages and macrophage subtypes such as Kupffer cells and cortical and medullary thymic macrophages (31). They have also been observed on high endothelial venules (31) and on subpopulations of dendritic cells (32), binding to a variety of foreign and self ligands. Members in this class have a similar structure, comprised of a cytoplasmic tail, transmembrane domain, spacer region, α helical coiled coil domain, collagenous domain, and a C-terminal cysteine-rich domain. SCARA1/MSR1, the prototypical SR-A molecule, was the first scavenger receptor to be cloned and was initially isolated from bovine lung mRNA. It has subsequently been identified in other species, including mice and humans. There are three isoforms, identified as alternative splice variants encoded by the same gene, namely, SR-AI, SR-AII, and SR-AIII (33, 34). Other members of this class of scavenger receptors include MARCO, SCARA5, and scavenger receptor with C-type lectin domain (SRCL)-I/II, also designated collectin from placenta receptor-I (35).

The scavenger receptor currently designated as SCARA1 or MSR1 would now be referred to as SR-A1. SR-A1 is predominantly found in macrophages, monocytes, mast cells, and dendritic cells in both mice and humans (36). A diverse array of ligands is recognized by members of this class. SR-A1 binds to β-amyloid, heat shock proteins, surface molecules of Gram-positive and Gram-negative bacteria, hepatitis C virus (34), and modified LDL such as acetylated LDL and oxidized LDL (oxLDL), but not native LDL.

SR-A1.1, an alternatively spliced form of SR-A1 (currently referred to as SR-AII), is characterized by a shortened C terminus. SR-A1.2, another alternatively spliced form of SR-A1 (currently referred to as SR-AIII), is characterized by a truncated C terminus and remains trapped in the endoplasmic reticulum. The collagenous region of SR-A1 and SR-A1.1 has been identified as a ligand-binding domain (37). There would be no receptor designated as SR-A2 to avoid confusion with the current SR-AII (new designation of SR-A1.1)

Whereas SR-A1 and SR-A6 (currently known as MARCO) are primarily expressed in macrophages, SR-A3 (also referred to as SCARA3, cellular stress response [CSR]), SR-A4 (SCARA4, SRCL, collectin placenta 1 [CL-P1]), and SR-A5 (SCARA5) are expressed in a variety of other tissues and cell types, including the lung, placenta, intestine, heart, and epithelial cells (38). SR-A3 has been associated with protecting cells from the detrimental effects of reactive oxygen species (21). SR-A4 functions as an endocytic receptor for lipoproteins and mediates the recognition, internalization, and degradation of oxidatively modified LDL by vascular endothelial cells (39). SR-A5 (currently known as SCARA5) expression is restricted to epithelial cells within the testis, airway, thymus, and the adrenal gland. SR-A5 has the capacity to bind bacteria and may play an important role in host defense (27). Under normal conditions, in the absence of inflammation, the expression of SR-A6 is restricted to macrophages in the lymph nodes and marginal zone of the spleen. Studies have shown that SR-A6 mediates the clearance of bacteria from the lungs (40) and bloodstream (41).

Proposed member nomenclature
  • SR-A1: the protein currently known as MSR1, SCARA1 [prototype].

  • SR-A1.1: the protein currently known as SR-AII. This is an alternatively spliced form of SR-A1.

  • SR-A1.2: the protein currently known as SR-AIII. This is also an alternatively spliced form of SR-A1.

  • There would be no receptor designated as SR-A2. This exception was agreed on during the meeting to avoid confusion with the current SR-AII, which would now be designated as SR-A1.1.

  • SR-A3: the protein currently known as MSRL1 or APC7; the current gene name is SCARA3.

  • SR-A4: the protein currently referred to as scavenger receptor C-type lectin; the current gene name is SCARA4.

  • SR-A5: the protein currently known as TESR; the current gene name is SCARA5.

  • SR-A6: currently named MARCO; the gene name is SCARA2. The workshop participants recommended that the gene name be changed to SCARA6 for consistency.

Class B scavenger receptors: SR-B.

Class B scavenger receptors include receptors currently known as SR-BI, SR-BII, CD36, and LIMP2. Receptors belonging to this class are characterized by two transmembrane domains flanking an extracellular loop, with both the amino and carboxyl termini located within the cytoplasm. The extracellular domain of these receptors is extensively N-linked glycosylated, and this modification provides protection against proteases often found in inflammatory sites. CD36 is the prototype class B type I scavenger receptor and was initially identified as a receptor for thrombospondin (42), and in this capacity it modulates angiogenesis and cell-to-cell interactions. It is one of the most widely studied scavenger receptors and is involved in multiple aspects of macrophage biology, including migration and signaling and inflammatory processes such as foam cell formation. CD36 also plays an important role in the host immune response to fungi and bacteria and binds erythrocytes infected with the malaria parasite Plasmodium falciparum (43), as well as functions as a facilitator of long chain fatty acid uptake (44). It is expressed in many cell types, including insulin-responsive cells; hematopoietic cells such as platelets, monocytes, and macrophages; and endothelial cells and specialized epithelial cells in the breast and eye. Dr. Gerda Endemann and colleagues were the first to characterize CD36 as a receptor for oxLDL, thereby cementing its role as a scavenger receptor (30). CD36 also binds polyanionic ligands of both host (e.g., high-density lipoprotein [HDL]) (45) and pathogen (examples are Staphylococcus aureus and Candida albicans) (20, 46) origin, and it plays an important role in the recognition and endocytic uptake of oxidized phospholipids, apoptotic cells, and amyloid proteins (47). Dr. Cameron Stewart and colleagues have shown that CD36 (SR-B2) cooperates with TLR family members (TLR4 and TLR6) to activate the innate immune response to ligands that accumulate in Alzheimer’s disease and atherosclerosis, inducing proinflammatory mediators such as IL-1β and RANTES.

SR-B1 (also known as SCARB1 or SR-BI) was the first HDL receptor to be identified and mediates the selective transport of lipids, such as cholesteryl esters from HDL, from lipoproteins to cells (48, 49). SR-B1 is most highly expressed by hepatocytes and steroidogenic cells and is also found in cells within the arterial wall and macrophages in human and murine atherosclerotic lesions (50). SR-B1 has been shown to have a protective effect on atherosclerosis development; total body ablation of SR-B1 in apolipoprotein E knockout mice fed a normal chow diet led to severe coronary arterial atherosclerosis, myocardial infarction, and death (51). Ablation of SR-B1 in bone marrow cells of LDL receptor knockout mice also resulted in increased atherosclerosis, but not death, indicative of partial protection against atherosclerosis (52).

SR-BII, an alternatively spliced form of SR-BI, contains a distinctly different cytoplasmic tail than SR-BI. SR-BII is expressed in adrenal glands, testes, and liver, and it has been shown to mediate selective uptake of cholesteryl ester from HDL, with ∼4-fold lower efficiency than SR-BI (53).

One other member of the CD36 family of membrane proteins, LIMP2 (SR-B3), functions primarily in delivering β-glucocerebrosidase from the endoplasmic reticulum to lysosomes. SR-B3 has been identified as a cellular receptor for enterovirus 71 (EV71), coxsackievirus 7 (CVA7), CVA14, and CVA16 entry into host cells. SR-B3 also serves a role in viral uncoating, thereby increasing infection efficiency (21). Expression of SR-B3 on the cell membrane has not been confirmed.

Proposed member nomenclature
  • SR-B1: originally cloned as the HDL receptor, the gene name is SCARB1; protein is currently also known as SR-BI.

  • SR-B1.1: an alternatively spliced form of SR-B1, currently known as SR-BII.

  • SR-B2: the protein currently known as CD36 [prototype].

  • SR-B3: the protein currently known as LIMP2.

Class C scavenger receptors.

Class C scavenger receptors have been described in Drosophila (5), but there are currently no known mammalian class C scavenger receptors. This scavenger receptor class was not discussed because the workshop participants focused on mammalian scavenger receptors.

Class D scavenger receptors: SR-D.

CD68 is the only known member of the class D scavenger receptors. CD68, also known as macrosialin in mice, is a type I transmembrane glycoprotein that belongs to the lysosome-associated membrane protein family of molecules (54). There is a 300-aa extracellular region that is rich in threonine and serine, which may serve as an attachment site for carbohydrates, and a short cytoplasmic tail. Human CD68 shares 75% amino acid sequence identity to mouse CD68 in the extracellular region. CD68 is found on monocytes and tissue-specific macrophages in the peritoneum, lungs, liver, spleen, Langerhans cells, and microglia, and it serves as a scavenger receptor for oxLDL. CD68 is a differentiation marker of hematopoietic cells of the monocyte/macrophage lineage. It is mostly found in the late endosomal compartment in macrophages and dendritic cells, with limited expression on resting cells. CD68 plays a minor role in the binding and uptake of oxidized lipoproteins and apoptotic cells by macrophages (23). The proposed new nomenclature for this molecule is: SR-D1: currently known as CD68 [prototype].

Class E scavenger receptors: SR-E.

Class E scavenger receptors are type 2 transmembrane proteins with C-type lectin-like domains and demonstrated scavenger receptor activity; sequence homology alone is not sufficient to include a protein in this class of receptors. These proteins structurally belong to a subfamily of the C-type lectin (CLEC)–like NK cell receptor family. The NK receptor gene complex encodes a large number of CLEC-like receptors that are expressed on NK cells and other leukocytes. Analysis of the NK receptor gene complex in five species revealed variations in the sizes of gene clusters in each species that ranged from 22 to 75 clusters and are noted in these species: human (29 clusters), dog (22 clusters), cattle (32 clusters), rat (75 clusters), and mouse (57 clusters) (55). Among these gene clusters, the first two members of the CLEC family, lectin-like oxLDL receptor (LOX-1) and Dectin-1, have been well characterized and shown to have scavenger activity.

LOX-1 is expressed on macrophages and dendritic cells and binds oxidized LDL and the acute phase protein C-reactive protein (56). It was originally cloned from a bovine aortic endothelial cDNA expression library screened for receptors for oxidized LDL (57). LOX-1 is expressed on vascular endothelial cells, platelets, smooth muscle cells, adipocytes, and macrophages. In addition to binding oxidized LDL, LOX-1 has been implicated in recognizing other ligands, including apoptotic cells, Gram-positive bacteria, and Gram-negative bacteria (23, 56). A splicing variant of human LOX-1 lacking a lectin-like domain, called LOXIN, works as a dominant-negative isoform, forming a heterodimeric complex with LOX-1 (58).

Dectin-1 is expressed predominantly on myeloid cells (macrophages, dendritic cells, and neutrophils) and can be regulated by cytokines and microbial stimuli. Human Dectin-1 is alternatively spliced, resulting in two functional forms. This receptor recognizes various bacterial, fungal, and plant carbohydrates (β-1,3- and/or β-1→6-glucans) in addition to intact fungi and parasites (59). Dectin-1 mediates proinflammatory cytokine production in response to β-glucan particles, in conjunction with TLR2. It can also function as a phagocytic receptor through a novel Syk-independent pathway. Dectin-1 has been reported to act as a costimulatory molecule to activate both CD4 and CD8 T cells. Moreover, Dectin-1 is expressed on macrophages and dendritic cells in the medullary regions of the thymus, suggesting a role in thymocyte development (60).

Some CLEC family members are known to recognize pathogen-associated molecules. However, most of the members of the CLEC family have not been shown to have scavenger receptor activity. At this time, only LOX-1 and Dectin-1 would be classified as scavenger receptors using the definition proposed by the workshop participants.

Proposed member nomenclature
  • SR-E1: the protein currently known as LOX1. Gene name OLR1 [prototype].

  • SR-E1.1: alternatively spliced form of SR-E1 also known as LOXIN (no known scavenger receptor activity but works as a dominant-negative form).

  • SR-E2: the protein currently known as Dectin-1.

Class F scavenger receptors: SR-F.

There are currently three members belonging to the class F scavenger receptors. The first class F scavenger receptor (SCARF1) was identified as an endothelial receptor for modified LDL and is characterized by the presence of an extracellular ligand-binding domain, with multiple extracellular epidermal growth factor–like repeats, a transmembrane domain, and a long cytoplasmic tail that includes a serine/proline-rich region followed by a glycine-rich region. It was named scavenger receptor expressed by endothelial cells (SREC)-I (61) and later was also named SCARF1. SCARF1/SREC-I is also expressed in macrophages and functions to bind calreticulin and associated peptides, which are transported into the MHC class I pathway in macrophages and dendritic cells (23). SCARF1 also was shown to be a receptor for fungal pathogens and heat shock proteins (20, 34). Interestingly, a Caenorhabditis elegans ortholog of SCARF1, CED-1, plays a role in engulfing apoptotic cells and has been implicated in host defense (23). A recent report indicates that SCARF1, similar to CED-1, is also involved in the clearance of apoptotic cells (62).

A second isoform of SREC-I, SREC-II, was cloned by Dr. Hiroyuki Arai’s group (63) and was shown to be predominantly expressed in heart, placenta, lung, kidney, spleen, small intestine, and ovary. SREC-II is a type I transmembrane receptor containing N-terminal epidermal growth factor–like domains, a transmembrane domain, and a long cytoplasmic tail, and it engages in heterophilic interactions with SREC-I. In contrast to SREC-I that binds and internalizes modified LDL, SREC-II is unable to internalize modified LDL. The cytoplasmic domain of SREC-II is rich in arginine and lysine, whereas SREC-I is rich in serine and proline. The significance of these residues is not known at this time.

Another member of the SCARF family, multiple epidermal growth factor (EGF)–like domains (MEGF)10, recently has been shown to be a receptor for the protein amyloid-β in the brain, and it is thought to be involved in the pathogenesis of Alzheimer’s disease (23). It is not clear yet whether other MEGF family members, such as MEGF8, 9, and 11, also have scavenger receptor function because no functional studies have been published to date on these molecules.

Proposed member nomenclature
  • SR-F1: the protein currently known as SREC-I/SCARF1 [prototype].

  • SR-F2: the protein currently known as SREC-II/SCARF2.

  • SR-F3: the protein currently known as MEGF10.

Class G scavenger receptors: SR-G.

Currently, one receptor belongs to scavenger receptor class G, SR-PSOX/CXCL16. Dr. Takeshi Shimaoka and colleagues used expression cloning of a cDNA library from PMA-treated human monocytic THP-1 cells to identify scavenger receptors that bound oxLDL, and they discovered this receptor, which they called SR-PSOX (64). At about the same time, Drs. Jason Cyster and Michael Briskin discovered a new chemokine that was capable of activating the receptor, CXCR6 (also known as BONZO, STRL33 or TYMSTR), resulting in migration of T cells in vitro (65–67). This chemokine was named CXCL16 and was found to be identical to SR-PSOX in its amino acid sequence.

Studies show that the SR-PSOX/CXCL16 gene is located on chromosome 17p13, and its protein exists in both membrane and soluble forms (65). It is a type I transmembrane glycoprotein with a CXC chemokine motif, mucin stalk, and transmembrane and soluble domains. SR-PSOX/ CXCL16 does not share structural homology with other scavenger receptors. SR-PSOX/CXCL16 has the capacity to mediate adhesion and phagocytosis of bacteria by APCs (66). The membrane-bound form can function as an adhesion molecule for CXCR6-expressing T cells without requiring CXCR6-induced signal transduction and integrin activation.

This multifunctional transmembrane protein has a chemokine-like CXC motif and appears to be involved in several phases of an immune response, from Ag recognition to migration of immune cells to formation of inflammatory foci (68). The soluble form of SR-PSOX/CXCL16, produced from cleavage of the membrane-bound form, functions as a chemoattractant for activated T cells and bone marrow plasma cells via its receptor CXCR6 (69). The membrane-bound form acts as a scavenger receptor for oxLDL and facilitates phagocytosis of bacteria by APCs (69).

Proposed member nomenclature
  • SR-G1: the protein currently known as SR-PSOX/CXCL16 [prototype].

Class H scavenger receptors: SR-H.

Receptors in this class are transmembrane proteins that consist of Fasciclin, EGF-like and lamin type EGF-like (FEEL) domains. The currently known SR-H members are FEEL-1/Stabilin-1/CLEVER-1 and FEEL-2/stabilin-2/HARE. FEEL-1 is predominantly expressed in macrophages, mononuclear cells, hematopoietic stem cells, and endothelial cells, whereas FEEL-2 is found mainly in sinusoidal endothelial cells. FEEL-1 and FEEL-2 have been shown to be involved in lymphocyte adhesion, transmigration, angiogenesis, apoptotic cell clearance, and intracellular trafficking. FEEL-1 and FEEL- 2 also have been implicated in the clearance of aged RBCs by macrophages (70, 71) in a phosphatidylserine-dependent manner. FEEL-1 has been shown to directly interact with and is sufficient for phagocytosis of phosphatidylserine-coated beads. These results have yet to be confirmed in vivo. However, FEEL-1 and FEEL-2 double knockout mice have been shown to be impaired in the clearance of noxious blood factors (72).

Proposed member nomenclature
  • SR-H1: the protein currently known as FEEL-1, Stabilin-1 and CLEVER -1 [prototype].

  • SR-H2: the protein currently known as FEEL-2/Stabilin-2.

Class I scavenger receptors: SR-I.

Members of the class I scavenger receptors are primarily restricted to the monocytic lineage, of which CD163, the prototypic class I scavenger receptor, is expressed exclusively in monocytes and macrophages and binds to haptoglobin/hemoglobin (Hgb) complexes to promote the clearance of plasma Hgb via endocytosis during intravascular hemolysis. CD163 is a type I transmembrane protein that consists of an extracellular region composed of nine scavenger receptor cysteine-rich (SRCR) domains and a short cytoplasmic tail. CD163 was originally cloned from the spleen of a patient afflicted with hairy cell leukemia, characterized by a large number of tissue macrophages. It is a 130-kDa membrane glycoprotein, and was known as M130 prior to being given a CD designation. CD163 was also given the functional name “hemoglobin scavenger receptor” to describe its primary role in tissue macrophages (73). Its role as an Hgb receptor may contribute to enhancement of an anti-inflammatory response because the proinflammatory heme is converted to anti-inflammatory metabolites (74).

In addition to functioning as an Hgb receptor, CD163 appears to be involved in intracellular signaling, resulting in a protein-kinase–dependent signal and secretion of cytokines such as IL-6 and IL-10 (75). Several CD163 mRNAs arising from an alternatively spliced CD163 gene have been reported (73, 75). Confocal microscopy studies revealed that the shortest tail variant is predominantly present in the cell membrane, whereas the longer variants are located in the endosomal/Golgi cellular compartment (75). One short tail variant and two long tail variants have been shown to bind and internalize haptoglobin/Hgb complexes leading to lysosomal degradation of the complex. The short tail variant is the predominant isoform found in human blood, liver, and spleen, and most of the long tail variants appear in endosomal compartments (75).

CD163-L1 (M160), a long tail variant of CD163, is a type I transmembrane molecule structurally composed of scavenger receptor cysteine-rich domains, expressed by cells of the myeloid lineage, and may be involved in the differentiation of monocytes to macrophages. Two cytoplasmic splice variants of CD163-L1 have been identified thus far; these include the full-length variant (CD163L1α) with a cytoplasmic tail of 71 residues and the short tail variant (CD163-L1β) with 39 residues. CD163-L1α is the predominant membrane-associated form in several human tissues such as spleen, placental, and small intestine, whereas CD163-Lβ is mainly found in intracellular compartments (76). Studies to identify endogenous and microbial ligands of CD163-L1β are currently in progress.

Proposed member nomenclature
  • SR-I1: the protein currently known as CD163, M130 [prototype].

  • SR-I1.1: the CD163 long tail variant 1.

  • SR-I1.2: the CD163 long tail variant 2.

  • SR-I2: currently known as CD163B, M160.

Class J scavenger receptors: SR-J.

RAGE is currently the only member of the class J scavenger receptor group, and it is a member of the Ig superfamily of cell surface molecules capable of interacting with a broad spectrum of ligands, including advanced glycation end products, high mobility group protein box 1, and the S-100 protein. RAGE is composed of a single transmembrane domain that connects the ectodomain with a short cytoplasmic domain and an extracellular domain required for ligand recognition and binding. The extracellular domain comprises an N-terminal sequence and three Ig-like regions. RAGE is a pattern recognition receptor predominantly involved in the recognition of endogenous molecules released in the context of infection, physiological stress, or chronic inflammation (77). Signaling through RAGE mediates processes such as inflammation, oxidative stress, and apoptosis, which can lead to pathologies including atherosclerosis, diabetes, cancer, neurodegenerative disease, and stroke. RAGE signaling also mediates normal neuronal processes such as cell migration and neuronal differentiation. Studies assessing brain pathology in Alzheimer’s disease revealed that diseased brains expressed higher levels of RAGE in the vasculature and on neurons compared with normal brains (23). In addition to a membrane-bound form, a circulating portion of the protein known as “soluble” RAGE also has biological properties.

Proposed member nomenclature
  • SR-J1: the protein currently known as the membrane-bound form of RAGE/AGER [prototype].

  • SR-J1.1: the soluble form of RAGE.

Other potential scavenger receptors: SR-Others.

The SR-Others group refers to molecules with scavenger activity that do not belong to the current SR classes, but belong to other receptor families. These receptors include LDL receptor family proteins such as LRP1, LRP2/megalin, cubam (the cubilin/amnionless complex), ASGP, MR, and CD11b/CD18α. Classifying these receptors as scavenger receptors will require the input of the wider scientific community.

Conclusions

In addition to their functions as phagocytic receptors and innate immune recognition receptors, scavenger receptors also play an important role as regulators of inflammatory signaling. These receptors have been implicated in a number of physiological and pathological processes, including interactions with other innate immune receptors, delivery of ligands to different cellular compartments, and Ag presentation. Furthermore, the roles of these receptors in neurodegenerative diseases, diabetes, and other metabolic disorders, as well as their potential as targets for therapeutic interventions to treat various disorders, warrant further study. Having a standardized nomenclature as described in this report would help to overcome current ambiguities in communication about specific scavenger receptors and, perhaps, remove a major barrier for researchers in other fields to enter the scavenger receptor field.

This report serves as an initial step in presenting the proposed nomenclature to the research community. A Web site has been established to invite comments from fellow investigators in response to the proposed nomenclature. The Web site is https://respond.niaid.nih.gov/ScavengerReceptors/, which will be open for public comment from March 1 through July 31, 2014. Additionally, the National Institute of Allergy and Infectious Diseases is organizing several discussion sessions at the following upcoming national meetings: Experimental Biology 2014 (April 29, 2014; http://experimentalbiology.org/2014/Home.aspx) in San Diego, CA; IMMUNOLOGY 2014 in Pittsburgh, PA (May 4, 2014; http://www.immunology2014.org/); and FOCIS 2014 (June 25, 2014; http://www.focisnet.org/focis-2014) in Chicago, IL. These sessions will be open to the meeting attendees to provide the broader scientific community with the opportunity to offer their comments and recommendations on the proposed scavenger receptor nomenclature. The National Institute of Allergy and Infectious Diseases plans to publish the final nomenclature recommendations in a subsequent publication in The Journal of Immunology, based on the comments received at these meetings and at the scavenger receptor nomenclature Web site. The final nomenclature will also be communicated to the International Union of Pharmacology to facilitate distribution to scientists working in areas related to pharmacology and biological target research.

Disclosures

M.K. has patents covering SR-AI/II; one SR-BI patent is used as a license to the Massachusetts Institute of Technology. There are several SR-BI patents pending. S.K.M. is a minority shareholder of a biotechnology company, Affinicon, which exploits CD163 for drug targeting. The remaining authors have no financial conflicts of interest.

Acknowledgments

We are grateful to Prof. Siamon Gordon for his invaluable input and suggestions for the scavenger receptor nomenclature workshop and proposed recommendations.

Footnotes

  • Abbreviations used in this article:

    CLEC
    C-type lectin
    CL-P1
    collectin placenta 1
    EGF
    epidermal growth factor
    FEEL
    Fasciclin, epidermal growth factor–like and lamin type epidermal growth factor–like
    HDL
    high-density lipoprotein
    Hgb
    hemoglobin
    LDL
    low-density lipoprotein
    LDLR
    low-density lipoprotein receptor
    LOX-1
    lectin-like oxidized low-density lipoprotein receptor 1
    MARCO
    macrophage receptor with collagenous structure
    MEGF
    multiple epidermal growth factor–like domains
    RAGE
    receptor for advanced glycation end products
    SRCL
    scavenger receptor with C-type lectin domain
    SRCR
    scavenger receptor cysteine-rich
    SREC
    scavenger receptor expressed by endothelial cells
    SR-PSOX
    scavenger receptor that binds phosphatidylserine and oxidized lipids.

References

  1. ↵
    1. Goldstein J. L.,
    2. Y. K. Ho,
    3. S. K. Basu,
    4. M. S. Brown
    . 1979. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA 76: 333–337.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Brown M. S.,
    2. J. L. Goldstein
    . 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 52: 223–261.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Russell D. W.,
    2. T. Yamamoto,
    3. W. J. Schneider,
    4. C. J. Slaughter,
    5. M. S. Brown,
    6. J. L. Goldstein
    . 1983. cDNA cloning of the bovine low density lipoprotein receptor: feedback regulation of a receptor mRNA. Proc. Natl. Acad. Sci. USA 80: 7501–7505.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Sege R. D.,
    2. K. Kozarsky,
    3. D. L. Nelson,
    4. M. Krieger
    . 1984. Expression and regulation of human low-density lipoprotein receptors in Chinese hamster ovary cells. Nature 307: 742–745.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Krieger M.
    1997. The other side of scavenger receptors: pattern recognition for host defense. Curr. Opin. Lipidol. 8: 275–280.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Gu B. J.,
    2. B. M. Saunders,
    3. S. Petrou,
    4. J. S. Wiley
    . 2011. P2X7 is a scavenger receptor for apoptotic cells in the absence of its ligand, extracellular ATP. J. Immunol. 187: 2365–2375.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Shibata M.,
    2. J. Ishii,
    3. H. Koizumi,
    4. N. Shibata,
    5. N. Dohmae,
    6. K. Takio,
    7. H. Adachi,
    8. M. Tsujimoto,
    9. H. Arai
    . 2004. Type F scavenger receptor SREC-I interacts with advillin, a member of the gelsolin/villin family, and induces neurite-like outgrowth. J. Biol. Chem. 279: 40084–40090.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Murphy P. M.,
    2. M. Baggiolini,
    3. I. F. Charo,
    4. C. A. Hébert,
    5. R. Horuk,
    6. K. Matsushima,
    7. L. H. Miller,
    8. J. J. Oppenheim,
    9. C. A. Power
    . 2000. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52: 145–176.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Riggs B. L.,
    2. R. Baron,
    3. W. J. Boyle,
    4. M. Drexner,
    5. S. Manolagas,
    6. T. J. Martin,
    7. A. F. Stewart,
    8. T. Suda,
    9. H. Yasuda,
    10. J. Aubin,
    11. D. Goltzman,
    12. The American Society for Bone and Mineral Research President’s Committee on Nomenclature
    . 2000. Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. Bone 27: 761–764.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Klos A.,
    2. E. Wende,
    3. K. J. Wareham,
    4. P. N. Monk
    . 2013. International Union of Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 65: 500–543.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Lodge D.
    2009. The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature. Neuropharmacology 56: 6–21.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Brown M. S.,
    2. S. K. Basu,
    3. J. R. Falck,
    4. Y. K. Ho,
    5. J. L. Goldstein
    . 1980. The scavenger cell pathway for lipoprotein degradation: specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages. J. Supramol. Struct. 13: 67–81.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Fogelman A. M.,
    2. M. E. Haberland,
    3. J. Seager,
    4. M. Hokom,
    5. P. A. Edwards
    . 1981. Factors regulating the activities of the low density lipoprotein receptor and the scavenger receptor on human monocyte-macrophages. J. Lipid Res. 22: 1131–1141.
    OpenUrlAbstract
  14. ↵
    1. Kodama T.,
    2. P. Reddy,
    3. C. Kishimoto,
    4. M. Krieger
    . 1988. Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 85: 9238–9242.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Kodama T.,
    2. M. Freeman,
    3. L. Rohrer,
    4. J. Zabrecky,
    5. P. Matsudaira,
    6. M. Krieger
    . 1990. Type I macrophage scavenger receptor contains α-helical and collagen-like coiled coils. Nature 343: 531–535.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Rohrer L.,
    2. M. Freeman,
    3. T. Kodama,
    4. M. Penman,
    5. M. Krieger
    . 1990. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II. Nature 343: 570–572.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Dunne D. W.,
    2. D. Resnick,
    3. J. Greenberg,
    4. M. Krieger,
    5. K. A. Joiner
    . 1994. The type I macrophage scavenger receptor binds to Gram-positive bacteria and recognizes lipoteichoic acid. Proc. Natl. Acad. Sci. USA 91: 1863–1867.
    OpenUrlAbstract/FREE Full Text
    1. Krieger M.,
    2. S. Acton,
    3. J. Ashkenas,
    4. A. Pearson,
    5. M. Penman,
    6. D. Resnick
    . 1993. Molecular flypaper, host defense, and atherosclerosis. Structure, binding properties, and functions of macrophage scavenger receptors. J. Biol. Chem. 268: 4569–4572.
    OpenUrlFREE Full Text
    1. El Khoury J.,
    2. S. E. Hickman,
    3. C. A. Thomas,
    4. L. Cao,
    5. S. C. Silverstein,
    6. J. D. Loike
    . 1996. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature 382: 716–719.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Means T. K.,
    2. E. Mylonakis,
    3. E. Tampakakis,
    4. R. A. Colvin,
    5. E. Seung,
    6. L. Puckett,
    7. M. F. Tai,
    8. C. R. Stewart,
    9. R. Pukkila-Worley,
    10. S. E. Hickman,
    11. et al
    . 2009. Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J. Exp. Med. 206: 637–653.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Canton J.,
    2. D. Neculai,
    3. S. Grinstein
    . 2013. Scavenger receptors in homeostasis and immunity. Nat. Rev. Immunol. 13: 621–634.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Gordon S.
    2002. Pattern recognition receptors: doubling up for the innate immune response. Cell 111: 927–930.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Wilkinson K.,
    2. J. El Khoury
    . 2012. Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer’s disease. Int. J. Alzheimers Dis. 2012: 489456.
    OpenUrlPubMed
  22. ↵
    1. Suzuki H.,
    2. Y. Kurihara,
    3. M. Takeya,
    4. N. Kamada,
    5. M. Kataoka,
    6. K. Jishage,
    7. O. Ueda,
    8. H. Sakaguchi,
    9. T. Higashi,
    10. T. Suzuki,
    11. et al
    . 1997. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386: 292–296.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Fraser I.,
    2. D. Hughes,
    3. S. Gordon
    . 1993. Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor. Nature 364: 343–346.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Elomaa O.,
    2. M. Kangas,
    3. C. Sahlberg,
    4. J. Tuukkanen,
    5. R. Sormunen,
    6. A. Liakka,
    7. I. Thesleff,
    8. G. Kraal,
    9. K. Tryggvason
    . 1995. Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages. Cell 80: 603–609.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Jiang Y.,
    2. P. Oliver,
    3. K. E. Davies,
    4. N. Platt
    . 2006. Identification and characterization of murine SCARA5, a novel class A scavenger receptor that is expressed by populations of epithelial cells. J. Biol. Chem. 281: 11834–11845.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Pugin J.,
    2. I. D. Heumann,
    3. A. Tomasz,
    4. V. V. Kravchenko,
    5. Y. Akamatsu,
    6. M. Nishijima,
    7. M. P. Glauser,
    8. P. S. Tobias,
    9. R. J. Ulevitch
    . 1994. CD14 is a pattern recognition receptor. Immunity 1: 509–516.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Stahl P. D.,
    2. R. A. Ezekowitz
    . 1998. The mannose receptor is a pattern recognition receptor involved in host defense. Curr. Opin. Immunol. 10: 50–55.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Endemann G.,
    2. L. W. Stanton,
    3. K. S. Madden,
    4. C. M. Bryant,
    5. R. T. White,
    6. A. A. Protter
    . 1993. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268: 11811–11816.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Hughes D. A.,
    2. I. P. Fraser,
    3. S. Gordon
    . 1995. Murine macrophage scavenger receptor: in vivo expression and function as receptor for macrophage adhesion in lymphoid and non-lymphoid organs. Eur. J. Immunol. 25: 466–473.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Becker M.,
    2. A. Cotena,
    3. S. Gordon,
    4. N. Platt
    . 2006. Expression of the class A macrophage scavenger receptor on specific subpopulations of murine dendritic cells limits their endotoxin response. Eur. J. Immunol. 36: 950–960.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Gough P. J.,
    2. D. R. Greaves,
    3. H. Suzuki,
    4. T. Hakkinen,
    5. M. O. Hiltunen,
    6. M. Turunen,
    7. S. Y. Herttuala,
    8. T. Kodama,
    9. S. Gordon
    . 1999. Analysis of macrophage scavenger receptor (SR-A) expression in human aortic atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 19: 461–471.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Plüddemann A.,
    2. C. Neyen,
    3. S. Gordon
    . 2007. Macrophage scavenger receptors and host-derived ligands. Methods 43: 207–217.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Ohtani K.,
    2. Y. Suzuki,
    3. S. Eda,
    4. T. Kawai,
    5. T. Kase,
    6. H. Keshi,
    7. Y. Sakai,
    8. A. Fukuoh,
    9. T. Sakamoto,
    10. H. Itabe,
    11. et al
    . 2001. The membrane-type collectin CL-P1 is a scavenger receptor on vascular endothelial cells. J. Biol. Chem. 276: 44222–44228.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Ingersoll M. A.,
    2. R. Spanbroek,
    3. C. Lottaz,
    4. E. L. Gautier,
    5. M. Frankenberger,
    6. R. Hoffmann,
    7. R. Lang,
    8. M. Haniffa,
    9. M. Collin,
    10. F. Tacke,
    11. et al
    . 2010. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 115: e10–e19.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Acton S.,
    2. D. Resnick,
    3. M. Freeman,
    4. Y. Ekkel,
    5. J. Ashkenas,
    6. M. Krieger
    . 1993. The collagenous domains of macrophage scavenger receptors and complement component C1q mediate their similar, but not identical, binding specificities for polyanionic ligands. J. Biol. Chem. 268: 3530–3537.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Whelan F. J.,
    2. C. J. Meehan,
    3. G. B. Golding,
    4. B. J. McConkey,
    5. D. M. Bowdish
    . 2012. The evolution of the class A scavenger receptors. BMC Evol. Biol. 12: 227.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Selman L.,
    2. K. Skjodt,
    3. O. Nielsen,
    4. C. Floridon,
    5. U. Holmskov,
    6. S. Hansen
    . 2008. Expression and tissue localization of collectin placenta 1 (CL-P1, SRCL) in human tissues. Mol. Immunol. 45: 3278–3288.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Arredouani M.,
    2. Z. Yang,
    3. Y. Y. Ning,
    4. G. Qin,
    5. R. Soininen,
    6. K. Tryggvason,
    7. L. Kobzik
    . 2004. The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. J. Exp. Med. 200: 267–272.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. van der Laan L. J. W.,
    2. E. A. Döpp,
    3. R. Haworth,
    4. T. Pikkarainen,
    5. M. Kangas,
    6. O. Elomaa,
    7. C. D. Dijkstra,
    8. S. Gordon,
    9. K. Tryggvason,
    10. G. Kraal
    . 1999. Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. J. Immunol. 162: 939–947.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Asch A. S.,
    2. J. Barnwell,
    3. R. L. Silverstein,
    4. R. L. Nachman
    . 1987. Isolation of the thrombospondin membrane receptor. J. Clin. Invest. 79: 1054–1061.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Ockenhouse C. F.,
    2. J. D. Chulay
    . 1988. Plasmodium falciparum sequestration: OKM5 antigen (CD36) mediates cytoadherence of parasitized erythrocytes to a myelomonocytic cell line. J. Infect. Dis. 157: 584–588.
    OpenUrlFREE Full Text
  42. ↵
    1. Coburn C. T.,
    2. F. F. Knapp Jr.,
    3. M. Febbraio,
    4. A. L. Beets,
    5. R. L. Silverstein,
    6. N. A. Abumrad
    . 2000. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J. Biol. Chem. 275: 32523–32529.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Gu X.,
    2. B. Trigatti,
    3. S. Xu,
    4. S. Acton,
    5. J. Babitt,
    6. M. Krieger
    . 1998. The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain. J. Biol. Chem. 273: 26338–26348.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Stuart L. M.,
    2. J. Deng,
    3. J. M. Silver,
    4. K. Takahashi,
    5. A. A. Tseng,
    6. E. J. Hennessy,
    7. R. A. B. Ezekowitz,
    8. K. J. Moore
    . 2005. Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J. Cell Biol. 170: 477–485.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Stewart C. R.,
    2. L. M. Stuart,
    3. K. Wilkinson,
    4. J. M. van Gils,
    5. J. Deng,
    6. A. Halle,
    7. K. J. Rayner,
    8. L. Boyer,
    9. R. Zhong,
    10. W. A. Frazier,
    11. et al
    . 2010. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11: 155–161.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Acton S.,
    2. A. Rigotti,
    3. K. T. Landschulz,
    4. S. Xu,
    5. H. H. Hobbs,
    6. M. Krieger
    . 1996. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271: 518–520.
    OpenUrlAbstract
  47. ↵
    1. Krieger M.
    1999. Charting the fate of the “good cholesterol”: identification and characterization of the high-density lipoprotein receptor SR-BI. Annu. Rev. Biochem. 68: 523–558.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Ashraf M. Z.,
    2. N. Gupta
    . 2011. Scavenger receptors: implications in atherothrombotic disorders. Int. J. Biochem. Cell Biol. 43: 697–700.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Braun A.,
    2. B. L. Trigatti,
    3. M. J. Post,
    4. K. Sato,
    5. M. Simons,
    6. J. M. Edelberg,
    7. R. D. Rosenberg,
    8. M. Schrenzel,
    9. M. Krieger
    . 2002. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ. Res. 90: 270–276.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Covey S. D.,
    2. M. Krieger,
    3. W. Wang,
    4. M. Penman,
    5. B. L. Trigatti
    . 2003. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler. Thromb. Vasc. Biol. 23: 1589–1594.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Webb N. R.,
    2. P. M. Connell,
    3. G. A. Graf,
    4. E. J. Smart,
    5. W. J. S. de Villiers,
    6. F. C. de Beer,
    7. D. R. van der Westhuyzen
    . 1998. SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells. J. Biol. Chem. 273: 15241–15248.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Song L.,
    2. C. Lee,
    3. C. Schindler
    . 2011. Deletion of the murine scavenger receptor CD68. J. Lipid Res. 52: 1542–1550.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Hao L.,
    2. J. Klein,
    3. M. Nei
    . 2006. Heterogeneous but conserved natural killer receptor gene complexes in four major orders of mammals. Proc. Natl. Acad. Sci. USA 103: 3192–3197.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Yoshimoto, R., Y. Fujita, A. Kakino, S. Iwamoto, T. Takaya, and T. Sawamura. 2011. The discovery of LOX-1, its ligands and clinical significance. Cardivasc. Drugs Ther. 25: 379–391.
  55. ↵
    1. Sawamura T.,
    2. N. Kume,
    3. T. Aoyama,
    4. H. Moriwaki,
    5. H. Hoshikawa,
    6. Y. Aiba,
    7. T. Tanaka,
    8. S. Miwa,
    9. Y. Katsura,
    10. T. Kita,
    11. T. Masaki
    . 1997. An endothelial receptor for oxidized low-density lipoprotein. Nature 386: 73–77.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Biocca S.,
    2. I. Filesi,
    3. R. Mango,
    4. L. Maggiore,
    5. F. Baldini,
    6. L. Vecchione,
    7. A. Viola,
    8. G. Citro,
    9. G. Federici,
    10. F. Romeo,
    11. G. Novelli
    . 2008. The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerization. J. Mol. Cell. Cardiol. 44: 561–570.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Herre J.,
    2. J. A. Willment,
    3. S. Gordon,
    4. G. D. Brown
    . 2004. The role of Dectin-1 in antifungal immunity. Crit. Rev. Immunol. 24: 193–203.
    OpenUrlCrossRefPubMed
  58. ↵
    1. Reid D. M.,
    2. M. Montoya,
    3. P. R. Taylor,
    4. P. Borrow,
    5. S. Gordon,
    6. G. D. Brown,
    7. S. Y. Wong
    . 2004. Expression of the β-glucan receptor, Dectin-1, on murine leukocytes in situ correlates with its function in pathogen recognition and reveals potential roles in leukocyte interactions. J. Leukoc. Biol. 76: 86–94.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Adachi H.,
    2. M. Tsujimoto,
    3. H. Arai,
    4. K. Inoue
    . 1997. Expression cloning of a novel scavenger receptor from human endothelial cells. J. Biol. Chem. 272: 31217–31220.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Ramirez-Ortiz Z. G.,
    2. W. F. Pendergraft III.,
    3. A. Prasad,
    4. M. H. Byrne,
    5. T. Iram,
    6. C. J. Blanchette,
    7. A. D. Luster,
    8. N. Hacohen,
    9. J. El Khoury,
    10. T. K. Means
    . 2013. The scavenger receptor SCARF1 mediates the clearance of apoptotic cells and prevents autoimmunity. Nat. Immunol. 14: 917–926.
    OpenUrlCrossRefPubMed
  61. ↵
    1. Ishii J.,
    2. H. Adachi,
    3. J. Aoki,
    4. H. Koizumi,
    5. S. Tomita,
    6. T. Suzuki,
    7. M. Tsujimoto,
    8. K. Inoue,
    9. H. Arai
    . 2002. SREC-II, a new member of the scavenger receptor type F family, trans-interacts with SREC-I through its extracellular domain. J. Biol. Chem. 277: 39696–39702.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Shimaoka T.,
    2. N. Kume,
    3. M. Minami,
    4. K. Hayashida,
    5. H. Kataoka,
    6. T. Kita,
    7. S. Yonehara
    . 2000. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J. Biol. Chem. 275: 40663–40666.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Matloubian M.,
    2. A. David,
    3. S. Engel,
    4. J. E. Ryan,
    5. J. G. Cyster
    . 2000. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. 1: 298–304.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Sheikine Y.,
    2. A. Sirsjö
    . 2008. CXCL16/SR-PSOX: a friend or a foe in atherosclerosis? Atherosclerosis 197: 487–495.
    OpenUrlCrossRefPubMed
  65. ↵
    1. Wilbanks A.,
    2. S. C. Zondlo,
    3. K. Murphy,
    4. S. Mak,
    5. D. Soler,
    6. P. Langdon,
    7. D. P. Andrew,
    8. L. Wu,
    9. M. Briskin
    . 2001. Expression cloning of the STRL33/BONZO/TYMSTRligand reveals elements of CC, CXC, and CX3C chemokines. J. Immunol. 166: 5145–5154.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Fukumoto N.,
    2. T. Shimaoka,
    3. H. Fujimura,
    4. S. Sakoda,
    5. M. Tanaka,
    6. T. Kita,
    7. S. Yonehara
    . 2004. Critical roles of CXC chemokine ligand 16/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis. J. Immunol. 173: 1620–1627.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Shimaoka T.,
    2. T. Nakayama,
    3. K. Hieshima,
    4. N. Kume,
    5. N. Fukumoto,
    6. M. Minami,
    7. K. Hayashida,
    8. T. Kita,
    9. O. Yoshie,
    10. S. Yonehara
    . 2004. Chemokines generally exhibit scavenger receptor activity through their receptor-binding domain. J. Biol. Chem. 279: 26807–26810.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Park S. Y.,
    2. M. Y. Jung,
    3. S. J. Lee,
    4. K. B. Kang,
    5. A. Gratchev,
    6. V. Riabov,
    7. J. Kzhyshkowska,
    8. I. S. Kim
    . 2009. Stabilin-1 mediates phosphatidylserine-dependent clearance of cell corpses in alternatively activated macrophages. J. Cell Sci. 122: 3365–3373.
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Park S. Y.,
    2. M. Y. Jung,
    3. H. J. Kim,
    4. S. J. Lee,
    5. S. Y. Kim,
    6. B. H. Lee,
    7. T. H. Kwon,
    8. R. W. Park,
    9. I. S. Kim
    . 2008. Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ. 15: 192–201.
    OpenUrlCrossRefPubMed
  70. ↵
    1. Schledzewski K.,
    2. C. Géraud,
    3. B. Arnold,
    4. S. Wang,
    5. H. J. Gröne,
    6. T. Kempf,
    7. K. C. Wollert,
    8. B. K. Straub,
    9. P. Schirmacher,
    10. A. Demory,
    11. et al
    . 2011. Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. J. Clin. Invest. 121: 703–714.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Kristiansen M.,
    2. J. H. Graversen,
    3. C. Jacobsen,
    4. O. Sonne,
    5. H. J. Hoffman,
    6. S. K. Law,
    7. S. K. Moestrup
    . 2001. Identification of the haemoglobin scavenger receptor. Nature 409: 198–201.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Thomsen J. H.,
    2. A. Etzerodt,
    3. P. Svendsen,
    4. S. K. Moestrup
    . 2013. The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging. Oxid. Med. Cell. Longev. 2013: 523652.
    OpenUrlPubMed
  73. ↵
    1. Nielsen M. J.,
    2. M. Madsen,
    3. H. J. Møller,
    4. S. K. Moestrup
    . 2006. The macrophage scavenger receptor CD163: endocytic properties of cytoplasmic tail variants. J. Leukoc. Biol. 79: 837–845.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Moeller J. B.,
    2. M. J. Nielsen,
    3. M. P. Reichhardt,
    4. A. Schlosser,
    5. G. L. Sorensen,
    6. O. Nielsen,
    7. I. Tornøe,
    8. J. Grønlund,
    9. M. E. Nielsen,
    10. J. S. Jørgensen,
    11. et al
    . 2012. CD163-L1 is an endocytic macrophage protein strongly regulated by mediators in the inflammatory response. J. Immunol. 188: 2399–2409.
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. Ibrahim Z. A.,
    2. C. L. Armour,
    3. S. Phipps,
    4. M. B. Sukkar
    . 2013. RAGE and TLRs: relatives, friends or neighbours? Mol. Immunol. 56: 739–744.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Immunology: 192 (5)
The Journal of Immunology
Vol. 192, Issue 5
1 Mar 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Standardizing Scavenger Receptor Nomenclature
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Standardizing Scavenger Receptor Nomenclature
Mercy PrabhuDas, Dawn Bowdish, Kurt Drickamer, Maria Febbraio, Joachim Herz, Lester Kobzik, Monty Krieger, John Loike, Terry K. Means, Soren K. Moestrup, Steven Post, Tatsuya Sawamura, Samuel Silverstein, Xiang-Yang Wang, Joseph El Khoury
The Journal of Immunology March 1, 2014, 192 (5) 1997-2006; DOI: 10.4049/jimmunol.1490003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Standardizing Scavenger Receptor Nomenclature
Mercy PrabhuDas, Dawn Bowdish, Kurt Drickamer, Maria Febbraio, Joachim Herz, Lester Kobzik, Monty Krieger, John Loike, Terry K. Means, Soren K. Moestrup, Steven Post, Tatsuya Sawamura, Samuel Silverstein, Xiang-Yang Wang, Joseph El Khoury
The Journal of Immunology March 1, 2014, 192 (5) 1997-2006; DOI: 10.4049/jimmunol.1490003
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Conclusions
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Minimal Information about MHC Multimers (MIAMM)
  • The Minority Scientists’ Experience: Challenging and Overcoming Barriers to Enhancing Diversity and Career Advancement
  • Metabolic Regulation of Inflammation and Its Resolution: Current Status, Clinical Needs, Challenges, and Opportunities
Show more IMMUNOLOGY NOTES AND RESOURCES

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606